Deutsche Bank Downgrades Sanofi (SNY) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Jefferies Downgrades Sanofi (SNY) to Hold
October 29, 2014 8:54 AM EDTJefferies downgraded Sanofi (NYSE: SNY) from Buy to Hold.
For an analyst ratings summary and ratings history on Sanofi click here. For more ratings news on Sanofi click here.
Shares of Sanofi closed at $48.07 yesterday.
... MoreBofA/Merrill Lynch Downgrades Sanofi-Aventis (SNY) to Neutral on CEO Removal
October 29, 2014 8:47 AM EDTBofA/Merrill Lynch downgraded Sanofi-Aventis (NYSE: SNY) from Buy to Neutral with a price target of $48.00 after the announcement that it has unanimously voted to remove Chris Viehbacher from his position as CEO.
Analyst Graham Parry said the news is negative for several... More
Barclays Downgrades Sanofi (SNY) to Equalweight
October 29, 2014 8:35 AM EDTBarclays downgraded Sanofi (NYSE: SNY) from Overweight to Equalweight.
For an analyst ratings summary and ratings history on Sanofi click here. For more ratings news on Sanofi click here.
Shares of Sanofi closed at $48.07 yesterday.
... MoreSanofi (SNY) Reports Q3 EPS of EUR1.47
October 28, 2014 6:42 AM EDTSanofi (NYSE: SNY) reported Q3 EPS of EUR1.47, EUR0.01 better than the analyst estimate of EUR1.46. Revenue for the quarter came in at EUR8.78 billion.
On diabetes, the company said, "Third-quarter sales of the Diabetes division reached 1,799 million, an increase of 8.3%. Year-to-date sales of the Diabetes division increased 12.5% to 5,249 million. Lantus® sales increased 8.1% to 1,567 million in the third... More
